HER2+ Early Stage Breast Cancer | Norton Healthcare

Indication: HER2+ Early Stage Breast Cancer

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast 11)

Sub-indication: Breast Cancer

Study Type: Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AstraZeneca

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.